Save information for later
Sign Up

Learn About Multiple Sulfatase Deficiency

What is the definition of Multiple Sulfatase Deficiency?

Multiple sulfatase deficiency is a condition that mainly affects the brain, skin, and skeleton. Because the signs and symptoms of multiple sulfatase deficiency vary widely, researchers have split the condition into three types: neonatal, late-infantile, and juvenile.

What are the causes of Multiple Sulfatase Deficiency?

Multiple sulfatase deficiency is caused by mutations in the SUMF1 gene. This gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones.

How prevalent is Multiple Sulfatase Deficiency?

Multiple sulfatase deficiency is estimated to occur in 1 per million individuals worldwide. More than 140 cases have been reported in the scientific literature.

Is Multiple Sulfatase Deficiency an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Multiple Sulfatase Deficiency Local Doctors?
Elite in Multiple Sulfatase Deficiency
Elite in Multiple Sulfatase Deficiency
Robert Koch Str. 40, 
Goettingen, NI, DE 

Lars Schlotawa practices in Goettingen, Germany. Mr. Schlotawa is rated as an Elite expert by MediFind in the treatment of Multiple Sulfatase Deficiency. His top areas of expertise are Multiple Sulfatase Deficiency, Metachromatic Leukodystrophy, Chondrodysplasia Punctata with Steroid Sulfatase Deficiency, CACH Syndrome, and Thrombectomy.

Elite in Multiple Sulfatase Deficiency
Pediatrics | Medical Genetics
Elite in Multiple Sulfatase Deficiency
Pediatrics | Medical Genetics

Childrens Health Care Associates Inc

3401 Civic Ctr Blvd, 
Philadelphia, PA 
Languages Spoken:
English

Rebecca Ahrens-Nicklas is a Pediatrics specialist and a Medical Genetics provider in Philadelphia, Pennsylvania. Dr. Ahrens-Nicklas is rated as an Elite provider by MediFind in the treatment of Multiple Sulfatase Deficiency. Her top areas of expertise are Multiple Sulfatase Deficiency, Cardiomyopathic Lentiginosis, Chondrodysplasia Punctata with Steroid Sulfatase Deficiency, and Noonan Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Multiple Sulfatase Deficiency
Internal Medicine
Advanced in Multiple Sulfatase Deficiency
Internal Medicine
500 Plaza Court, Suite B, 
East Stroudsburg, PA 
Languages Spoken:
English

Jonathan Goldner is a primary care provider, practicing in Internal Medicine in East Stroudsburg, Pennsylvania. Dr. Goldner is rated as an Advanced provider by MediFind in the treatment of Multiple Sulfatase Deficiency. His top areas of expertise are High Cholesterol, Cirrhosis, Familial Combined Hyperlipidemia, Xanthoma, and Splenectomy.

What are the latest Multiple Sulfatase Deficiency Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG

Summary: This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).

Who are the sources who wrote this article ?

Published Date: May 17, 2021
Published By: National Institutes of Health